Fig. 6

IFITM3 suppress nuclear expression of FOXO3 to promote c-MYC expression and GC progression. A Immunoblotting analysis of FOXO3 in the nuclear and cytoplasmic fractions of IFITM3-overexpressing or control TMK-1 cells. B Immunoblotting analysis of c-MYC in IFITM3 overexpressing or control TMK-1 cells with HA-FOXO3-A3 overexpression. Cellular growth curves (C) and migration rates (D) of the indicated groups of TMK-1 cells as in (B) were determined by measurements of viable or migrated cells after treatments (*p < 0.05, **p < 0.01). E Sphere formation assays were performed to assess the influences of HA-FOXO3-A3 overexpression on IFITM3-overexpressing TMK-1 cells (Left panel, scale bar, 500 μm; right panel is the statistical results. *p < 0.05, **p < 0.01). F Chemosensitivities of the same indicated groups of TMK-1 cells were determined based on the relative number of cells survived after treatment with 5’FU (20 μg/ml) or cisplatin (3 μM) for 72 h. *p < 0.05, **p < 0.01